Why TherapeuticsMD Is Skyrocketing

By Chris Lange Updated Jan 13, 4:20PM EST · Published Dec 8, 11:05AM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Why TherapeuticsMD Is Skyrocketing — © Thinkstock

TherapeuticsMD Inc. (NYSEMKT: TXMD) was leading the health care sector in Tuesday’s session on positive top-line results from one of its late-stage trials. The company announced positive results from its pivotal Phase 3 Rejoice Trial of TX-004HR, an investigational, applicator-free vaginal estradiol softgel, for the treatment of moderate to severe dyspareunia.

For some background, dyspareunia is vaginal pain during sexual intercourse, a symptom of vulvar and vaginal atrophy (VVA) due to menopause. VVA is a chronic condition affecting nearly half of postmenopausal women in the United States that can significantly impair their quality of life.

Safety and efficacy analyses of the Rejoice Trial data are ongoing. TherapeuticsMD plans to submit Rejoice Trial results for presentation at future scientific meetings and for publication in peer-reviewed journals.

Robert G. Finizio, CEO of TherapeuticsMD, said:

We are extremely encouraged that all three doses of TX-004HR studied in the Rejoice Trial demonstrated positive results. With efficacy observed as early as two weeks and the convenience of the applicator-free vaginal softgel, we believe that, if approved, TX-004HR has the potential to offer a highly differentiated, new treatment option that meets the needs of the millions of postmenopausal women with VVA who are suffering from pain during sexual intercourse. We look forward to sharing the Rejoice Trial results and to submitting a New Drug Application for TX-004HR to the Food and Drug Administration as soon as the first half of 2016.

Sebastian Mirkin, M.D., Chief Medical Officer of TherapeuticsMD, added:

Nearly half of all postmenopausal women have VVA, yet few are treated with prescription therapy. The highly statistically significant efficacy results and safety profile from the Rejoice Trial are very promising. We are excited about the potential for TX-004HR to be a new treatment option with low systemic absorption for women with VVA suffering from moderate to severe dyspareunia.

Shares of TherapeuticsMD were last seen trading up over 45% at $9.62, with a consensus analyst price target of $17.40 and a 52-week trading range of $3.44 to $9.45.
[recirclink id=297576]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.